Benitec Biopharma Inc.
HealthcareNASDAQ:BNTC · NASDAQ Capital Market
+$0.13 today
Vol 0.07M · Avg 0.11M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-39.0%
avg -976.0%
ROIC
-42.6%
avg -296.8%
ROA
-38.1%
avg -103.2%
Analysis
ROA is currently the strongest return metric at -38.1% versus its period average of -103.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jerel A. Banks | Executive Chairman & Chief Executive Officer | $1.07M | — | 50 | $450,000.00 | 1.71% |
Sophie Mukadam | Chief Operating Officer | $940,439.00 | — | 45 | $500,000.00 | 1.90% |
Megan Joan Boston | CFO & Secretary | $870,813.00 | — | 53 | $200,000.00 | 0.76% |
Michael Graham | Head of Discovery & Founding Scientist | $135,274.00 | — | — | $1.00M | 3.81% |
Claudia Kloth | Senior Vice President of Manufacturing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$22.44M
Sells
0
$0.00
Net Sentiment
+$22.44M
Net buying
Most Active
SUVRETTA CAPITAL MANAGEMENT, LLC
14 transactions
1–10 of 14
Analysis
Insiders reported 14 buys worth $22.44M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $22.44M. SUVRETTA CAPITAL MANAGEMENT, LLC was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +23.6% | +34.6% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +23.6% over three years. Forward estimates point to Revenue at +34.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
XOMA Royalty Corp.
NASDAQ:XOMA
$524.09M
Neurogene Inc.
NASDAQ:NGNE
$459.84M
PureTech Health plc
NASDAQ:PRTC
$424.07M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$316.61M
I-Mab
IMAB
$235.66M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
Who manages BNTC?
Benitec Biopharma Inc. (BNTC) lists 5 active executives. The top listed executive is Jerel A. Banks, Executive Chairman & Chief Executive Officer.
Are BNTC insiders buying or selling?
Recent insider activity shows net buying of $91.96M.
Explore More
Continue the stock analysis
Jump to another research area for this company.